ImPact Biotech Secures FDA Approval for IND Application of Padeliporfin VTP in Pancreatic Cancer

ImPact Biotech, a clinical-stage biotechnology company, has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application, allowing the initiation of a Phase 1 study for Padeliporfin Vascular Targeted Photodynamic (VTP) therapy in patients with unresectable pancreatic adenocarcinoma (PDAC).

Barak Palatchi, the CEO of ImPact Biotech, expressed excitement about exploring the potential of Padeliporfin VTP in addressing the significant unmet needs in locally advanced pancreatic cancer. The company plans to commence the study in the first half of the coming year. Palatchi also highlighted the broader implications of this IND clearance, underscoring the conviction in their platform as a non-surgical alternative with the potential to enhance outcomes for patients with various solid tumors.

The Phase 1 study is a two-part, multi-center, non-randomized, open-label clinical trial. It aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Padeliporfin VTP therapy in patients with Stage 3, locally advanced, and unresectable PDAC. Part A will utilize a 3+3 dose-escalation design to evaluate the safety and tolerability of Padeliporfin VTP at ascending doses administered endovascularly via optical fiber, in combination with intravenous administration of Padeliporfin at a fixed dose. Part B will enroll an expansion cohort, dosing at the maximum tolerated dose identified in Part A, with the primary objective of evaluating preliminary efficacy.

Padeliporfin VTP therapy, described as a minimally invasive oncology platform for solid tumor treatment, combines surgery-like efficacy with the preservation of healthy tissue or organs. The therapy involves intravenous delivery of an inactive drug, Padeliporfin. Upon light activation, the drug induces rapid constriction of the blood supply in the illuminated area only, leading to targeted tumor necrosis. This process activates anti-tumor immunity, ultimately enhancing the eradication of cancer cells.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!